Pharvaris (NASDAQ:PHVS) Director Sells $558,850.08 in Stock

by · The Markets Daily

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) Director Robert Glassman sold 14,493 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $38.56, for a total transaction of $558,850.08. Following the completion of the transaction, the director directly owned 10,500 shares of the company’s stock, valued at approximately $404,880. The trade was a 57.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Glassman also recently made the following trade(s):

  • On Tuesday, September 15th, Robert Glassman sold 8,667 shares of Pharvaris stock. The stock was sold at an average price of $38.27, for a total value of $331,686.09.
  • On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total value of $300,400.00.

Pharvaris Price Performance

PHVS traded down $0.35 on Monday, reaching $36.02. The company’s stock had a trading volume of 653,689 shares, compared to its average volume of 412,750. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The business’s 50 day moving average is $35.37 and its 200 day moving average is $31.75. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, research analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on PHVS shares. Rosenblatt Securities set a $60.00 price objective on shares of Pharvaris in a research note on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. Citizens Jmp lifted their price target on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday, September 9th. Guggenheim boosted their price objective on Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, HSBC raised Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and a consensus price target of $59.87.

Get Our Latest Research Report on PHVS

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. venBio Partners LLC bought a new stake in shares of Pharvaris during the 2nd quarter valued at about $160,569,809. Wellington Management Group LLP lifted its holdings in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after acquiring an additional 274,034 shares during the last quarter. Commodore Capital LP boosted its stake in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares during the period. 5AM Venture Management LLC acquired a new position in Pharvaris in the second quarter valued at approximately $27,581,008. Finally, Seven Fleet Capital Management LP grew its holdings in shares of Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after purchasing an additional 457,804 shares during the last quarter.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

Read More